Point Roberts, WA, New York, NY - August 6, 2013 (Investorideas.com newswire) Investorideas.com, an investor research portal specializing in investing ideas in leading sectors including biotech and medical technology stocks, issues a trading alert for Aethlon Medical, Inc. (OTCQB: AEMD). The stock closed Monday’s trading session at $0.1870, gaining 0.0270 or 16.88% on over 1.9 Million shares. The stock traded as high as $0.20, its 52- week high.

The stock made its first run in July when it announced FDA approval of an Investigational Device Exemption (IDE) that allows the Company to initiate human feasibility studies of the Aethlon Hemopurifier® in the United States. The Hemopurifier ® is a first-in-class medical device that targets the rapid elimination of life-threatening infectious disease and cancer glycopathogens from circulation.

Nieves: The Next Major Silver Discovery ( 7/20/13)

History of Nieves to Date

Silver, and a number of other minerals, have been mined at Nieves since the Spanish discovered the outcrop in or about 1610.

We always say that, “You find a mine where there has been a mine.”

Written by Chris Berry, MBA - [ Discovery Investing Web Site ]

US Q2 GDP Beats Estimates, But that is Not the Real Story

The ISM Manufacturing Index also exceeded estimates, delivering a reading of 55.4 – it’s highest reading since June 2011- indicating growth in the US manufacturing base

The overall numbers are good, but not great; today’s release of the non-farm payrolls data should help confirm whether or not the US recovery is set to continue and perhaps accelerate

If the economy does “find its legs”, higher interest rates are a given. What to do?

Written by Chris Berry, MBA - [ Discovery Investing Web Site ]

Point Roberts, WA, New York, NY - August 2, 2013 (Investorideas.com newswire) Investorideas.com, an investor research portal specializing in investing ideas in leading sectors including biotech and medical technology stocks, issues a trading alert for Aethlon Medical, Inc. (OTCQB: AEMD), The stock is trading at 0.17, up 0.03 or 21.43% as of 2:25PM EDT on over 1.3 Million shares, with a high of $0.18.

In late July the company reported that Battelle, NxStage Medical (NASDAQ: NXTM), Inc. and Aethlon Medical (OTCQB: AEMD) won a contract from the Defense Advanced Research Projects Agency, or DARPA, to develop an innovative, new medical device that may save the lives of soldiers -- and civilians as well -- by treating sepsis.